卡铂联合吉西他滨每周给药治疗晚期非小细胞肺癌的临床疗效观察

摘要

目的：评价每周应用卡铂与吉西他滨治疗晚期非小细胞肺癌（NSCLC）的疗效及安全性。方法：52名未接受过化疗治疗的，所患 NSCLC 体积可测定的患者被纳入。患者接受吉西他滨（1000mg／m2 d1，8）及卡铂（AUC ＝2 d1，8）治疗，每三周为一个化疗疗程。结果：缓解率为33％（17／52）。疾病进展时间为17．2周，中位生存时间43．6周。1年生存率42．3％。主要毒副反应为血液系统毒性：3级或4级中性粒细胞减少（35％）及血小板减少（29％）。无其他严重毒副反应。结论：一线应用卡铂联合吉西他滨每周给药治疗晚期 NSCLC，耐受性好，有较好临床效果。%Objective:To evaluate the efficacy and safety of treatment with weekly carboplatin and gemcitabine in advanced non -small cell lung cancer (NSCLC).Methods:All 52 patients with NSCLC were included,who never re-ceived chemotherapy,and volume of tumor was measurable.Every three weeks as a course of chemotherapy,patients received gemcitabine 1 000mg/m2 and carboplatin AUC =2 in the course of day 1 and 8.Results:The remission rate was 33%(17 /52).Disease progression time was 17.2 weeks,and median survival time was 43.6 weeks.1 year sur-vival rate was 42.3% and main toxicity showed the blood toxicity with grade 3 or 4 neutropenia (35%)and thrombo-cytopenia (29%).There were no other severe toxic effects.Conclusion:The treatment in first line using carboplatin combined with gemcitabine weekly for advanced NSCLC showed good tolerance,which indicating good clinical appli-cation value.